We have developed an oil-in-water based nanoemulsion (NE) that induces strong systemic and mucosal immunity against a variety of pathogens when used as a mucosal adjuvant. In an effort to enhance the mucosal immune responses of NE, we co-formulated it with retinoic acid (NERA). RA, a vitamin A derivative, has been shown to orchestrate T cell homing towards the gut as well as IgA production by retinaldehyde dehydrogenase (RALDH) in dendritic cells (DCs). METHODS: To examine the efficacy of NERA in-vitro, we simulated invivo intranasal immunization in a co-culture model. We treated the epithelial cells with different formulations of NE, followed by co-culturing with dendritic and T cells. Further, animals were intranasally immunized with ova-albumin (Ova) in combination to NE (with and without RA) to study RALDH production by mucosal DCs, T cell gut homing, IgA production and Th1/Th2/Th17 cytokine production. RESULTS: NE alone induces RALDH activity in co-cultured DCs and induces gut homing marker expression in-vitro. Also, immunization with NE-Ova showed increased RALDH activity in DCs, resulting in increased IgA production as well as T cell gut homing. Furthermore, antibody titers and cytokine data suggested increased Th1/Th17 response while suppressing Th2. Vanderbilt University, Nashville, TN, 3 Vanderbilt Univ School of Medicine, Nashville, TN. RATIONALE: Our laboratory reported that prostaglandin I 2 (PGI 2 ) promotes immune tolerance in mice. Thus, we hypothesized that PGI 2 promotes the functionality of Tregs in vivo, in an adoptive-transfer model of allergic inflammation. METHODS: We utilized mice deficient in the receptor for PGI 2 , IP (IPKO). Splenic ovalbumin (OVA)-specific Tregs were isolated from wild-type (WT) and IPKO mice. OVA-specific CD4+ effector T cells (Teff) were isolated from the spleens of WT mice. Equal amounts of Teff and either WT or IPKO Tregs were retroorbitally transferred into RAG1 deficient mice. Another group of RAG1 deficient mice were transferred only Teff. RAG1 deficient recipients were challenged intranasally with OVA 1 day prior to and for 3 days post transfer. On day 4 post transfer the bronchoalveolar lavage (BAL) and lungs were harvested and examined for the presence of IL-13 by ELISA and flow cytometry. RESULTS: Compared to mice transferred only Teff, total IL-13 in the lungs and BAL was reduced by 46% (p<0.001) and 55% (p<0.001), respectively, in the mice transferred WT Tregs; however, there was no decrease in total IL-13 in the mice transferred IPKO Tregs. Furthermore, compared to mice transferred only Teff, total OVA-specific CD4+IL-13+ cells in the lungs were reduced by 32% (p<0.05) in the mice transferred WT Tregs, however, there was no decrease in these cells in mice transferred IPKO Tregs. (Data are expressed as Percent of Baseline, n58-15) CONCLUSIONS: Our data demonstrate that PGI 2 signaling promotes Treg function in vivo and suggests that PGI 2 may serve as a novel treatment for allergic diseases.
Vanderbilt University, Nashville, TN, 3 Vanderbilt Univ School of Medicine, Nashville, TN. RATIONALE: Our laboratory reported that prostaglandin I 2 (PGI 2 ) promotes immune tolerance in mice. Thus, we hypothesized that PGI 2 promotes the functionality of Tregs in vivo, in an adoptive-transfer model of allergic inflammation. METHODS: We utilized mice deficient in the receptor for PGI 2 , IP (IPKO). Splenic ovalbumin (OVA)-specific Tregs were isolated from wild-type (WT) and IPKO mice. OVA-specific CD4+ effector T cells (Teff) were isolated from the spleens of WT mice. Equal amounts of Teff and either WT or IPKO Tregs were retroorbitally transferred into RAG1 deficient mice. Another group of RAG1 deficient mice were transferred only Teff. RAG1 deficient recipients were challenged intranasally with OVA 1 day prior to and for 3 days post transfer. On day 4 post transfer the bronchoalveolar lavage (BAL) and lungs were harvested and examined for the presence of IL-13 by ELISA and flow cytometry. RESULTS: Compared to mice transferred only Teff, total IL-13 in the lungs and BAL was reduced by 46% (p<0.001) and 55% (p<0.001), respectively, in the mice transferred WT Tregs; however, there was no decrease in total IL-13 in the mice transferred IPKO Tregs. Furthermore, compared to mice transferred only Teff, total OVA-specific CD4+IL-13+ cells in the lungs were reduced by 32% (p<0.05) National Institutes of Allergic and Infectious Diseases/NIH, Bethesda, MD. RATIONALE: Glucocorticoids (GC) remain the most commonly used therapy for eosinophil-associated disorders (EAD). Prolonged treatment is associated with significant side effects and resistance that commonly lead to drug discontinuation. Whereas rapid disappearance of blood eosinophils following a single dose of GC is characteristic, the mechanisms by which this occurs is unknown. To explore this, we developed a novel radiolabeling technique to track eosinophils following GC administration in vivo in a rhesus macaque model. METHODS: Blood eosinophils were purified via negative selection from rhesus macaques using anti-CD64 antibody binding and magnetic bead negative selection. Eosinophil phenotype, viability and activation were assessed by flow cytometry. A >90% pure eosinophil fraction was labeled with Zirconium-89 oxine, re-injected into each animal, and tracked in vivousing positron-emission tomography (PET) imaging. In separate experiments, blood eosinophil counts were also monitored. RESULTS: In the absence of GC, PET imaging showed a rapid migration of eosinophils through the lungs to the bone marrow (n52), spleen and liver. Bone marrow homing of Zirconium-89 labeled eosinophils increased following administration of a single dose of GC (n51). This was accompanied by a CXCR4 up-regulation on blood eosinophils. The CXCR4 antagonist plerixafor significantly inhibited the decrease in blood eosinophilia at 2 hours post-administration of GC (P<0.01, n53). CONCLUSIONS: These findings suggest that GC-induced eosinopenia involves eosinophil migration to the bone marrow by a CXCR4-dependent mechanism. A better understanding of this process may help clarify mechanisms of GC resistance in EAD and lead to the development of more targeted therapeutic approaches.
